Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Return to homepage

Pharvaris NV (OQ:PHVS)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily
Jan 13, 2025 06:50 am ET
Pharvaris Outlines 2025 Strategic Priorities
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and...
Nov 13, 2024 04:10 pm ET
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced financial results for the third quarter ended...
Nov 12, 2024 06:50 am ET
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced that its management will participate in the...
Oct 24, 2024 08:00 am ET
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced data from seven posters that will be presented at...
Oct 16, 2024 06:50 am ET
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of multiple abstracts at several...
Oct 15, 2024 06:50 am ET
Pharvaris to Host Virtual Investor Event on October 23, 2024
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced it will host a virtual investor event to discuss...
Oct 03, 2024 06:50 am ET
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of six abstracts, two for oral...
Sep 05, 2024 06:50 am ET
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the planned initiation of CHAPTER-3, the pivotal...
Sep 05, 2024 06:49 am ET
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, is highlighting the differentiated profile of deucrictibant as a...
Sep 05, 2024 06:48 am ET
Pharvaris Presents Data at the Bradykinin Symposium 2024
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced a summary of data being presented at the ongoing...
Aug 28, 2024 06:50 am ET
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for oral...
Aug 14, 2024 06:50 am ET
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the financial results for the second quarter ended...
Jun 11, 2024 06:50 am ET
Pharvaris Announces Annual Meeting of Shareholders
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the annual general meeting of shareholders will...
Jun 04, 2024 06:50 am ET
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, recently presented data highlighting the unique pharmacological and...
May 13, 2024 06:50 am ET
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at...
May 08, 2024 04:10 pm ET
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the first quarter ended March...
Apr 10, 2024 04:10 pm ET
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the fourth quarter and year...
Apr 10, 2024 04:08 pm ET
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of David Nassif, J.D., as Chief...
Apr 04, 2024 06:50 am ET
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for presentation at...
Mar 18, 2024 06:50 am ET
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, presented at two recent congresses: the 3rd National Congress of...
Mar 06, 2024 06:50 am ET
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at two upcoming...
Mar 05, 2024 06:50 am ET
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that its management will participate in the Leerink Global...
Feb 22, 2024 06:50 am ET
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the upcoming presentation of two posters at the American Academy...
Feb 16, 2024 06:50 am ET
Pharvaris Announces Extraordinary Meeting of Shareholders
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the extraordinary general meeting of shareholders will take place...
Jan 26, 2024 06:50 am ET
Pharvaris to Present at the WSAAI Annual Meeting 2024
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for poster presentation at the...
Jan 22, 2024 06:50 am ET
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the U.S. Food and Drug Administration (FDA) has lifted the...
Jan 05, 2024 06:50 am ET
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today provided business updates and outlined its strategic priorities for 2024....
Dec 08, 2023 06:00 pm ET
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the presentation of one oral session and two posters at the...
Dec 06, 2023 08:31 am ET
Thinking about buying stock in Coinbase Global, Pharvaris, Kamada, Minerva Surgical, or Brilliant Acquisition?
NEW YORK, Dec. 6, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for COIN, PHVS, KMDA, UTRS, and BRLI.
Dec 06, 2023 07:02 am ET
Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
Pharvaris N.V. (“Pharvaris”, Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, announced today the pricing of an underwritten offering of (i)...
Dec 06, 2023 06:50 am ET
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the CHAPTER-1 Phase 2 clinical study...
Nov 30, 2023 06:50 am ET
Pharvaris to Present at the GA²LEN UCARE Conference 2023
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of one abstract for oral presentation and two...
Nov 15, 2023 06:50 am ET
Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of Stefan Abele, Ph.D., as Chief Technical...
Nov 09, 2023 11:00 am ET
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the presentation of two ePosters at the American College of...
Nov 02, 2023 06:50 am ET
Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the third quarter ended September 30, 2023...
Oct 30, 2023 06:50 am ET
Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the...
Oct 13, 2023 06:50 am ET
Pharvaris To Present at the APAAACI 2023 International Conference
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of an abstract oral presentation at the Asia...
Oct 04, 2023 07:34 am ET
Pharvaris To Present at the CIIC Fall 2023 Conference
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the...
Sep 19, 2023 06:50 am ET
Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, will attend the 2023 Cantor Global Healthcare Conference, taking place in New...
Sep 06, 2023 06:51 am ET
Pharvaris To Present at the 18th German Allergy Congress
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the...
Sep 06, 2023 06:50 am ET
Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, will attend the Morgan Stanley 21st Annual Global Healthcare Conference, taking...
Aug 23, 2023 06:50 am ET
Pharvaris To Present at the 2023 HAEi Regional Conference EMEA
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of three abstracts for presentation at the HAEi...
Aug 07, 2023 06:50 am ET
Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the second quarter ended June 30, 2023 and...
Jul 21, 2023 10:20 am ET
Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today shared data from the RAPIDe-1 Phase 2 clinical study of PHVS416...
Jun 26, 2023 06:50 am ET
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the U.S. Food and Drug Administration (FDA) has lifted the...
Jun 20, 2023 06:50 am ET
Pharvaris Announces $70 Million Private Placement Financing
Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated...
Jun 10, 2023 06:01 pm ET
Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced two presentations highlighting data from RAPIDe-1, a Phase 2...
Jun 01, 2023 06:50 am ET
Pharvaris Announces Annual Meeting of Shareholders
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the annual general meeting of shareholders will take place on...
May 08, 2023 06:50 am ET
Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the first quarter ended March 31, 2023 and...
May 06, 2023 01:00 pm ET
Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced two oral presentations and three poster presentations...
Apr 05, 2023 06:51 am ET
Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the fourth quarter and year ended December...
Mar 18, 2023 12:35 am ET
Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced an oral presentation of positive data from its Phase 2 RAPIDe-1...
Mar 02, 2023 06:50 am ET
Pharvaris to Present in Upcoming March Investor Conferences
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that management will participate in two upcoming investor...
Feb 24, 2023 06:50 am ET
Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced a poster detailing positive data from its Phase 2 RAPIDe-1 study...
Feb 08, 2023 06:50 am ET
Pharvaris to Present at SVB Securities Global Biopharma Conference
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that management will present at the SVB Securities Global...
Jan 09, 2023 06:50 am ET
Pharvaris Provides Regulatory, Clinical, and Corporate Updates
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today provided business updates and company highlights. Business Updates and...
Dec 09, 2022 09:55 am ET
Thinking about buying stock in Neurobo Pharmaceuticals, Palantir Technologies, Pharvaris NV, Li Auto, or IQIYI?
NEW YORK, Dec. 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NRBO, PLTR, PHVS, LI, and IQ.
Dec 08, 2022 07:39 am ET
Thinking about buying stock in Rent the Runway, Hello Group, Melco Resorts & Entertainment, Pharvaris NV, or Bilibili?
NEW YORK, Dec. 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RENT, MOMO, MLCO, PHVS, and BILI.
Dec 08, 2022 06:51 am ET
Pharvaris Reports Third Quarter 2022 Financial Results and Provides Business Update
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the third quarter ended September 30, 2022,...
Dec 08, 2022 06:50 am ET
Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the RAPIDe-1 Phase 2 clinical study,...
Nov 10, 2022 08:00 am ET
Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced it will be presenting two in-person “ePoster – Meet the Author”...
Oct 07, 2022 08:30 am ET
Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Global Leadership Workshop
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the presentation of preclinical and clinical data of PHA121, and...
Sep 30, 2022 06:50 am ET
Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the promotion of Annick Deschoolmeester to Chief Human Resources...